Lineage Capital Recaps Bioreclamation

Lineage Capital has sponsored a majoroity recapitalization of Bioreclamation Inc., a Westbury, N.Y.-based maker of control matrix material used by biotech and pharma companies in preclinical and clinical development. No financial terms were dislcosed. Mufson Howe Hunter & Co. advised Bioreclamation on the deal.

PRESS RELEASE

Bioreclamation, Inc. (Westbury, NY) is an industry leading manufacturer, processer, marketer and distributor of control matrix material used by biotechnology and pharmaceutical companies in preclinical and clinical development. The Company markets to drug developers research materials from over 32 different animal species, healthy human materials and disease-state human products covering nine disease categories. Bioreclamation’s customer base includes all of the major biotechnology and pharmaceutical firms domestically and abroad.

Mufson Howe Hunter & Company, LLC was hired as the Company’s exclusive financial advisor to explore various options for financing the on-going growth of the Company as well as to provide a significant liquidity event to the Company’s founding shareholders. Prior to marketing, Mufson Howe Hunter & Company conducted extensive financial, business and accounting due diligence, wrote a comprehensive Confidential Information Memorandum and prepared the Company for the transaction process. After conducting a targeted marketing process that resulted in multiple bidders for the business, Mufson Howe Hunter & Company concluded with a recapitalization whereby the shareholders achieved a significant liquidity event while maintaining a meaningful stake in the business.

Furthermore, in selecting Lineage Capital, LLC, the founding shareholders partnered with a private equity firm interested in financing the growth of Bioreclamation while also permitting them to retain significant corporate control.